Physicochemical Properties
| Molecular Formula | C28H24FN7O2 |
| Molecular Weight | 509.53 |
| Exact Mass | 509.2 |
| CAS # | 2406278-81-5 |
| PubChem CID | 146282356 |
| Appearance | Off-white to light yellow solid powder |
| LogP | 3.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 38 |
| Complexity | 801 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | C1=C(C2C(C=C1)=NC=CN=2)C(N[C@@H]1C[C@H](C1)C1N(C2C=CC=CC=2F)C(=NN=1)C1N=CC(OCC)=CC=1)=O |
| InChi Key | ARCOJIXZDJYBCH-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C28H24FN7O2/c1-2-38-19-10-11-23(32-16-19)27-35-34-26(36(27)24-9-4-3-7-21(24)29)17-14-18(15-17)33-28(37)20-6-5-8-22-25(20)31-13-12-30-22/h3-13,16-18H,2,14-15H2,1H3,(H,33,37) |
| Chemical Name | N-[3-[5-(5-ethoxypyridin-2-yl)-4-(2-fluorophenyl)-1,2,4-triazol-3-yl]cyclobutyl]quinoxaline-5-carboxamide |
| Synonyms | OM-153 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | TNKS1 ( IC50 = 13 nM ); TNKS2 ( IC50 = 2 nM ); Wnt/β-catenin ( IC50 = 0.63 nM ) |
| ln Vitro |
OM-153 exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties, no off-target liabilities, improved pharmacokinetic profile in mice, and picomolar IC50 inhibition (0.63 nM) in a cellular (HEK293) WNT/β-catenin signaling reporter assay[1]. OM-153 significantly inhibits the growth of COLO 320DM cells at GI50 values of 10 nM and GI25 values of 2.5 nM (concentrations that result in 50% and 25% growth inhibition, respectively), but has no effect on the growth of RKO cells[2]. OM-153 exhibits an antiproliferative effect and inhibits WNT/β-catenin, YAP, and MYC signaling in human cancer cell lines[2]. |
| ln Vivo |
OM-153 (0.1–10 mg/kg; p.o.; twice daily; for 34 days) decreases WNT/β-catenin signaling and tumor progression in COLO 320DM colon carcinoma xenografts[2]. OM-153 enhances anti-PD-1 immune checkpoint inhibition and antitumor effect in a B16-F10 mouse melanoma model[2]. |
| Animal Protocol |
CB17-SCID mice bearing COLO 320DM cells 10 mg/kg, 3.3 mg/kg, 1 mg/kg, 0.33 mg/kg, or 0.1 mg/kg p.o.; twice daily; for 34 days |
| References |
[1]. Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II. J Med Chem. 2021;64(24):17936-17949. [2]. The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models. Cancer Research Communications (2022) 2 (4): 233-245. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~196.3 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (4.91 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9626 mL | 9.8130 mL | 19.6259 mL | |
| 5 mM | 0.3925 mL | 1.9626 mL | 3.9252 mL | |
| 10 mM | 0.1963 mL | 0.9813 mL | 1.9626 mL |